Claims for Patent: 7,598,257

Summary for Patent: 7,598,257

Title:	Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
Abstract:	The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
Inventor(s):	Rodgers; James D. (Landenberg, PA), Shepard; Stacey (Voorhees, NJ)
Assignee:	Incyte Corporation (Wilmington, DE)
Application Number:	11/637,545
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,598,257
Patent Claims:	1. A compound which is 3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]prop- anenitrile or a pharmaceutically acceptable salt thereof. 2. A compound which is (3R)-3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl- ]propanenitrile or a pharmaceutically acceptable salt thereof. 3. A compound which is (3S)-3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl- ]propanenitrile or a pharmaceutically acceptable salt thereof. 4. A composition comprising the compound of any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier. 5. The composition of claim 4 which is suitable for oral or topical administration. 6. A method of treating myeloid metaplasia with myelofibrosis (MMM) in a patient comprising administering to said patient a therapeutically effective amount of a compound of any one of claims 1 to 3, or pharmaceutically acceptable salt thereof. 7. A method of treating polycythemia vera (PV) in a patient comprising administering to said patient a therapeutically effective amount of a compound of any one of claims 1 to 3, or pharmaceutically acceptable salt thereof. 8. A method of treating essential thrombocythemia (ET) in a patient comprising administering to said patient a therapeutically effective amount of a compound of any one of claims 1 to 3, or pharmaceutically acceptable salt thereof.